8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

_______________

Form 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (date of earliest event reported):

June 4, 2008

SCOLR Pharma, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-31982	91-1689591
(State or other jurisdiction of incorporation)	(Commission File No.)	(I.R.S. Employer Identification No.)

3625 132nd Avenue SE, Suite 400

Bellevue, WA 98006

(Address of principal executive offices)

(425) 373-0171

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

£ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

£ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

£ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

£ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

Representatives of SCOLR Pharma, Inc. will use the materials attached hereto as Exhibit 99.1 in investor presentations from time to time. We have also posted the presentation materials on our company website at www.scolr.com.

Please refer to page 2 of Exhibit 99.1 for a discussion of certain forward-looking statements included in the presentation materials, including without limitation information about the status of our product development programs and timelines. These forward-looking statements involve risks and uncertainties, including activities, events or developments that we expect, believe or anticipate will or may occur in the future. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including our ability to successfully develop new formulations and complete research and development, including pre-clinical and clinical studies, our ability to raise additional funds, the continuation of arrangements with our product development partners and customers, competition, government regulation and approvals, and general economic conditions. In order to obtain regulatory approvals for the commercial sale of potential products utilizing our CDT platform, we may be required to complete clinical trials in humans to demonstrate the safety and efficacy, or in certain cases, the bioequivalence, of the products. However, we may not be able to commence or complete these clinical trials in any specified time period, or at all, either because the appropriate regulatory agency objects or for other reasons. We plan to continue the costly process of simultaneously conducting clinical trials and preclinical research for multiple product candidates. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission. Such filings are available on our website or at www.sec.gov.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Presentation materials for the investor presentation by SCOLR Pharma, Inc.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SCOLR PHARMA, INC.
Dated:  June 4, 2008	By:	/s/ Daniel O. Wilds
		Daniel O. Wilds President and Chief Executive Officer

3

EX-99.1

*Copyright©2008, SCOLR Pharma, Inc.

1

*June 5, 2008

SCOLR Pharma, Inc.

Amex:DDD

SCOLR Pharma

2008 Annual Meeting of Stockholders

*Copyright©2008, SCOLR Pharma, Inc.

2

*June 5, 2008

SCOLR Pharma, Inc.

Amex:DDD

Forward-Looking Statements

§This presentation contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including without limitation statements about our product
development programs and timelines, that involve significant risks
and uncertainties. These statementsrepresent management’s
present expectations of future events and are subject to a number
of important factors that could cause actual results to differ
materially from those described in the forward-looking
statements.

§Please refer to the risk factors and other cautionary language
included in our reports and other filings with the Securities and
Exchange Commission and available on our website.

§We assume no obligation to update these forward-looking
statements.

*Copyright©2008, SCOLR Pharma, Inc.

3

*June 5, 2008

SCOLR Pharma, Inc.

Amex:DDD

Progress Since Last Annual Meeting

nCompleted two of three product performance pivotal trials
to evaluate the safety and efficacy of SCOLR’s 12 hour
CDT-Ibuprofen tablet

nContinued preparations for submission of SCOLR’s first
ANDA for 12 hour CDT-Pseudoephedrine tablet

nEntered into a collaboration and license agreement with Dr
Reddy’s laboratories for the development and
commercialization of an undisclosed oral prescription drug

nCompleted initial CDT formulations and preclinical
evaluations on Peramivir

nCompleted internal development of SCOLR’s prototype
once-daily CDT-based risperidone and rivastigmine
formulations

nReceived fifth patent under CDT platform

*Copyright©2008, SCOLR Pharma, Inc.

4

*June 5, 2008

SCOLR Pharma, Inc.

Amex:DDD

Progress Since Last Annual Meeting

nExpanded Perrigo collaboration with introduction of fifth
CDT-based nutritional product

nRenewed collaboration agreement with consumer products
company on undisclosed application of CDT technology

nAdded new directors to board further enhancing
pharmaceutical industry experience

nAdvanced discussions with potential partners

nCompleted registered direct offering for gross proceeds of
$4.1 million in December 2007

nCompleted $4.1 million lease buyout agreement and
identified new premium lab space at reduced cost

nStreamlined operations and expenses in order to fund
business through 2009

*Copyright©2008, SCOLR Pharma, Inc.

5

*June 5, 2008

SCOLR Pharma, Inc.

Amex:DDD

*Kalorama Information 2007 (Cited by In-Pharma
Technologist.com 1-17-2007

SCOLR Pharma: A Differentiated Oral Drug Delivery
Company

§Proprietary, validated technology - CDT® platform

§Greater extended-release flexibility

§Enhanced bioavailability

§Less complex/cost-effective formulations

§Develops, licenses and commercializes novel products with
significant market potential

§Distributed risk pipeline of internal and partnered targets with
significant market potential

§Significant partnerships include

§Dr. Reddy’s

§BioCryst Pharmaceuticals

§Perrigo

§Market is forecast to increase 48% to reach $52.1 billion in
revenues by 2010*

*Copyright©2008, SCOLR Pharma, Inc.

6

*June 5, 2008

SCOLR Pharma, Inc.

Amex:DDD

CDT® - - A Better Oral Drug Delivery Alternative

§New generation of less complex, cost-effective tablet/capsule
formulations

§Uses standard GRAS ingredients and equipment

§Based on a portfolio of 5 recently issued and pending patents for

§Robust, predictable and programmable extended-release

§Improved solubility/absorption/permeability/consistency

§Gastro-intestinal (GI) stable formulations

§Applicable to broad range of drug types and classes and consumer
products

§18 validating clinical studies, n > 550

§Successful commercialization/scale-up > 250 million tablets shipped

*Copyright©2008, SCOLR Pharma, Inc.

7

*June 5, 2008

SCOLR Pharma, Inc.

Amex:DDD

Important Current Collaborations Expand Pipeline
Potential

§Dr. Reddy’s Laboratory (DRL) - Collaboration & License Agreement

§Develop/commercialize CDT-based cardiopulmonary drug

§BioCryst Pharmaceuticals - Research Collaboration

§Develop an oral formulation of Peramivir, an injectible drug
currently under development by BioCryst for the treatment of
seasonal and life threatening influenza, including the avian flu

§Perrigo Company- Development and Distribution Alliance

§5 CDT-based nutraceutical products currently on the market

§Largest provider of store brand nutritional and over-the-counter
(OTC) pharmaceutical products in the U.S.

§Global Consumer Products Company - Collaboration Extended 12/07

§Novel application of SCOLR technology for existing global
consumer product

CDT Difference: Broadly Applicable, Flexible, Cost-Effective Sustained Release

CDT Difference: Less Complex Solubility/Absorption Enhancement

Notes: (1) Market Data Sources - IMS, Data Monitor, industry analysts, company disclosures, SCOLR estimates.

Current OTC Development Targets
$9 billion Combined Market(1)

*Copyright©2008, SCOLR Pharma, Inc.

11

*June 5, 2008

SCOLR Pharma, Inc.

Amex:DDD

Rx products for size reference
only

6 tabs/24 hr

6 tabs/24 hr

2 tabs/24 hr

Not Available in US

SCOLR CDT-Ibuprofen: First 12-hour Extended-Release
Tablets

CDT tablets compared to existing immediate-release tablets

12hr CDT- Ibuprofen bioequivalent to 3 IR Tablets

§Repeated clinical results from prior trials - Consistency in data

§Pivotal Clinical results - “SCOLR test formulation can be clinically substituted with the reference listed
drug.”

SCOLR CDT-Ibuprofen: Demonstrated Stability over 2 years

Undetectable
impurity level
compared to
standard

No detectable impurities

No change in tablet performance

N=26 subjects

as reported by
AAIPharma

CDT-Pseudoephedrine: Offers Same Drug Load with Smaller,

More Cost-Effective Tablets

Initial CDT-Pseudoephedrine testing bioequivalent to Sudafed® 12 hour (Reference Product)

Notes: (1) Market data sources - IMS, Data Monitor, industry analysts, company disclosures, SCOLR estimates.

(2) Based on animal and clinical study results

Current Rx Development Targets
$ 3.6 billion Combined Market(1)

Notes: (1) Market data sources - IMS, Data Monitor, industry analysts, company disclosures, SCOLRestimates.

New Rx Development Targets
$2.3 billion Combined Market(1)

*Copyright©2008, SCOLR Pharma, Inc.

17

*June 5, 2008

SCOLR Pharma, Inc.

Amex:DDD

2008 Strategic Growth Initiatives

§Complete pivotal trials and label comprehension study
for 12 hour CDT-Ibuprofen

§Submit ANDA for 12 hour CDT-Pseudoephedrine

§Expand Nutritional “All Day” product suite

§Advance existing portfolio targets

§Apply CDT platform to new targets

§Enter new alliance and partnership agreements

§Build intellectual property estate/portfolio

§Complete $4.1 million lease buyout and relocate
facility

*Copyright©2008, SCOLR Pharma, Inc.

18

*June 5, 2008

SCOLR Pharma, Inc.

Amex:DDD

Management

§Daniel O. Wilds, President, CEO and Director, appointed 2003

§Previously, Chairman, President and CEO of Northwest Biotherapeutics,
President and CEO of Shiloov Biotechnologies (USA), Adeza Biomedical and
Medisense, President of Baxter’s Chemotherapy Service, and President and
COO of Travenol-Genetech, a joint venture between Baxter International and
Genentech

§Alan M. Mitchel, Sr. VP Business & Legal Affairs and CLO, appointed
2005

§Extensive legal, business and corporate finance experience most recently at
Gray Cary, Former outside counsel for SCOLR

§Stephen J. Turner, VP Research and Development, CTO, appointed 2003

§Employed in positions of increasing responsibility at SCOLR since 1999. Built
SCOLR’s R&D and Information Technology Functions

§Richard M. Levy, CPA, VP of Finance, CFO, appointed 2006

§Previously Corporate Controller for Safeco Insurance, CFO for the Specialty
Finance Segment and Corporate Controller for Washington Mutual Bank,
Senior Vice President and Controller of Texas operations at Bank of America

§Tanya M. Raco, Assoc. VP of Regulatory and Quality Affairs, appointed
2006

§Employed in positions of increasing responsibility at SCOLR since 1997. Built
SCOLR’s Regulatory and Quality Assurance Functions

*Copyright©2008, SCOLR Pharma, Inc.

19

*June 5, 2008

SCOLR Pharma, Inc.

Amex:DDD

Balance Sheet and Capital Structure

Balance Sheet Data

March 31, 2008(In Thousands)

Cash and cash equivalents        $9,500

Settlement from lease buyout (April, 2008)        4,100

          Total $13,600

Working Capital           $  9,500

Total Assets         11,300

Total Debt      171

(In Millions)

Common Shares Outstanding                 41.1

Fully - - Diluted Shares                 48.4

*Copyright©2008, SCOLR Pharma, Inc.

20

*June 5, 2008

SCOLR Pharma, Inc.

Amex:DDD

®

SCOLR Pharma
Well Positioned for the Future

§Large, growing markets

§Unique, broadly applicable, patented technology platform
with important benefits

§Expanding prescription and OTC pipeline with multiple
clinical and pre-clinical candidates

§Royalty revenues from existing products

§Value driving milestones

§Experienced management team

Growing OTC & Rx Pipeline with Market > $15 B

 21

Consumer Product Pipeline with Markets > $ 2 B

*Copyright©2008, SCOLR Pharma, Inc.

23

*June 5, 2008

SCOLR Pharma, Inc.

Amex:DDD